The global idiopathic pulmonary fibrosis treatment market reached a value of US$ 3,278 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 5,268 Million by 2027, exhibiting at a CAGR of 7.89% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Idiopathic pulmonary fibrosis (IPF) refers to a progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is characterized by the formation of scar tissue within the lungs that starts at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. It is diagnosed through chest imaging studies, lung biopsies, pulmonary function tests and antibody tests. Two of the most commonly used antifibrotic therapy includes nintedanib and pirfenidone-based drugs, which improves lung functioning and minimizes the risks of acute respiratory deterioration. They are often coupled with oxygen therapy and palliative care to provide comfort and improve the recovery of the patient.
The increasing prevalence of fibrotic diseases, along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products, such as cigarettes, is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes is considered as one of the most common causes for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favoring the growth of the market. Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global idiopathic pulmonary fibrosis treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Long-term Care Facilities
Breakup by Region:
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.
|Base Year of the Analysis
||Drug Class, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players?
- What is the degree of competition in the industry?